Latest research on Tolterodine

Tolterodine is an antimuscarinic drug that is used to treat urinary incontinence. Tolterodine acts on M2 and M3 subtypes of muscarinic receptors.

Latest findings

Tolterodine and/or intravesical Bupivacaine were used as analgesia in patients with bladder spasm after prostate operation. [source, 2016]
In a randomized controlled trial, the use of Tolterodine was shown to have a low incidence of central nervous system side effects and was effective in the treatment of older patients with urinary symptoms attributable to overactive bladder. [source, 2016]
In this study, Tolterodine is largely used as analgesia in patients with bladder spasm after prostate operation. [source, 2016]
Various antimuscarinics, such as Oxybutynin, propiverine, Tolterodine, Trospium Chloride, Fesoterodine, and solifenacin were used in the treatment of OAB, and they have been widely used with their proven effectiveness and stability. [source, 2015]
In a review article that compared Fesoterodine and Tolterodine, it has been reported that Fesoterodine is superior to Tolterodine due to its OAB symptoms. [source, 2015]
However, the rate of discontinuation of the drug due to side effects is more common in Fesoterodine rather than Tolterodine. [source, 2015]
Although in their study for comparison of Fesoterodine and Tolterodine, Du Beau et al21 found out that both drugs are similar in terms of efficacy, dry mouth and constipation symptoms were more commonly observed in the Fesoterodine group. [source, 2015]
A study in which placebo and Fesoterodine have been compared in patients that gave sub-optimal response to the Tolterodine, puts forward that treatment efficacy of Fesoterodine is fair, and can be well-tolerated in terms of anticholinergic side effects.22 [source, 2015]
In a meta-analysis that included 1805 patients and comparison of solifenacin and Tolterodine by Liu et al9 solifenacin was found to be superior in terms of OAB symptoms. [source, 2015]
In another study that compared solifenacin and Tolterodine, the efficacy levels of those drugs were found to be similar, and anticholinergic side effects were substantially less common in the solifenacin group. [source, 2015]